Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease

By M. Risner, A. Saunders, J. Altman, G. C. Ormandy, S. Craft, I. Foley, M. Zvartau-Hind, D. Hosford, A. Roses, for the Rosiglitazone in Alzheimer's Disease Study Group. The Pharmacogenomics Journal, 2006

687 citations recorded by the source corpus.

Subfields: Pharmacology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/271b0f77be9c7aaa9a06f9f52392de4792c1f30a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

1. Sérgio T. Ferreira
2. F. D. De Felice

In Physiology

1. William E. Klunk
2. K. Viola
3. Chester A. Mathis
4. Sérgio T. Ferreira
5. F. D. De Felice
6. P. Velasco
7. M. Lambert
8. Kewei Chen

In Psychiatry and Mental health

1. Kewei Chen
2. Eric M. Reiman
3. Chester A. Mathis
4. William E. Klunk
5. C. Zhong
6. Zhichun Chen

Citations in the corpus

• Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers (2009, background): “Recent clinical trials indicate that insulin-sensitizing drugs such as rosiglitazone improve cognition and memory in both AD and type 2 diabetes patients (28, 43, 50, 51).”
• Mechanisms Underlying Inflammation in Neurodegeneration (2010, neutral): “Recent studies suggest that these drugs have preventive activity in AD (Risner et al., 2006; Watson et al., 2005).”
• BRAIN FUEL METABOLISM, AGING AND ALZHEIMER’S DISEASE (2010, background): “More recent controlled clinical trials confirm that short-term improvement can occur in cognitive tests when individuals with mild to moderate AD are provided with an exogenous source of glucose, ketones, insulin, or insulin sensitizers [78,184–188].”
• Epidemiology of Alzheimer Disease (2012, neutral): “Another study (Risner et al. 2006) in patients with AD lacking the APOE-14 allele showed significant although small improvements in cognitive and functional improvement in response to rosiglitazone, whereas in a study by Sato et al. (2009) , treatment with 15 – 30 mg pioglitazone daily for 6 months…”
• Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. (2013, background): “Paradoxically, rosiglitazone seems to be effective only in APOE-4-negative subjects but not in APOE- 4-positive subjects (Risner et al., 2006).”
• Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease (2009, background): “Preliminary studies have raised the possibility that 4 carriers and noncarriers may respond differently to certain treatments (30).”